作为右侧和左侧结肠癌的预后生物标志物的HLAII类多态
Amani Attia1, Awatef Lagha1,2, Amel Mezlini3
1Laboratory of Mycology, Pathologies, and Biomarkers (LR16ES05), University of Tunis El Manar, (UTM), Faculty of Sciences of Tunis (FST), Tunis, Tunisia.
The International journal of biological markers
|January 5, 2024
概括
人类白细胞抗原 (HLA) II类DRB1和DQB1基因变异与结肠癌风险有关. 特定的HLA-II等位基因可以作为早期检测和预测结肠癌患者治疗反应的生物标志物.
科学领域:
- 免疫遗传学 免疫遗传学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 结肠癌 (CC) 是一种普遍存在的全球恶性瘤.
- 识别右侧 (RCC) 和左侧 (LCC) CC 的预后生物标志物对于早期检测至关重要.
- 人类白细胞抗原II类 (HLA-II) 与CC倾向的关联已被建议.
研究的目的:
- 调查DRB1和DQB1等位基因与LCC和RCC风险之间的关联.
- 探索HLA-II多态的潜力,作为结肠癌的生物标志物.
主要方法:
- 该研究包括93名CC患者和100名健康对照.
- 使用聚合酶链反应序列特异性原始物 (PCR-SSP) 进行了HLAII类等位基因的基因定型.
主要成果:
- DRB1*03显示出与CC的积极关联,而DRB1*11,DRB1*13,DQB1*03,DQB1*05则呈负相关性.
- 哈普洛型分析确定了与增加或减少CC风险相关的特定DRB1-DQB1组合.
- 分层分析表明DRB1*11与转移风险和治疗耐受性有关,而DQB1*03与淋巴结入侵有关.
结论:
- DRB1和DQB1多态可能成为未来的生物标志物,用于早期检测RCC和LCC.
- 这些遗传标记可以帮助识别患有特定结肠癌亚型风险较高的个体.
- 这些发现表明,HLA-II等位基因在预测结肠癌转移和治疗反应方面具有潜力.
更多相关视频
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
03:18Non-LTR Retrotransposons
11.5K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.5K